From: Expert opinion on detecting and treating depression in palliative care: A Delphi study
Drug 0 = not useful, 10 = very useful | Experts comments |
---|---|
Mirtazapine Round 1: Median 9.0 (7-10); n = 11 Round 2: Median 9.0 (7-10); n = 11 | -Some data, good profile regarding side effects, at this time most used -Seems well tolerated -When side effects on sleep and appetite are handy -Too soft -Has useful sedative properties and well tolerated -My first-line - evidence is that it is more effective than SSRIs and appetite stimulant and sedative qualities are useful side effects |
Citalopram Round 1: Median 9.0 (5-10); n = 11 Round 2: Median 9.0 (5-10); n = 13 | -Side effects due to its antIHJJistaminic action |
Venlafaxine Round 1: Median 7.5 (0-10); n = 8 Round 2: Median 8.0 (0-9); n = 13 | -Less side effects than tricyclics -Useful if patient needs help for sedation -If depression is associated with chronic high level of anxiety -Not straightforward - discontinuation symptoms common. Cardiac toxicity |
Sertraline Round 1: Median 7.0 (2-10); n = 11 Round 2: Median 7.5 (0-10); n = 12 | -Favourable side effect profile -Interaction with dopamine system could give different and more side effects than other SSRIs -Least adverse effects, presently best available |
Escitalopram Round 1: Median 8.0 (0-10); n = 10 Round 2: Median 7.0 (0-10); n = 13 | -Not cost effective alternative to citalopram -Better tolerated than R-citalopram and less interaction with cytocrome 450 2D6 |
Amitriptyline Round 1: Median 5.0 (1-9); n = 10 Round 2: Median 4.0 (0-8); n = 12 | -Side-effects -Too sedative, effect too delayed, frequent compliance obstacle due to side effects -If indicated for neuropathic pain -For individual TCAs I don't think there is sufficient evidence to differentially rate, although clinically I would favour those drugs that are used most often in palliative care anyway e.g. amitriptyline -An excellent antidepressant |
Paroxetine Round 1: Median 5.5 (0-9); n = 10 Round 2: Median 3.0 (0-7); n = 13 | -Too many pharmacological interactions -Interactions and withdrawal problems -No place - withdrawal syndrome |
Fluoxetine Round 1: Median 3.0 (0-6); n = 10 Round 2: Median 3.0 (0-6); n = 13 | -Too long half time, not useful for physically ill people -Long t1/2 and interactions -Too disinhibitory, but not better antidepressant than other SSRIs |
Imipramine Round 1: Median 5.0 (0-6); n = 7 Round 2: Median 2.0 (0-8); n = 11 | -Just in patients with depressive history who have already utilized before |
Nortriptyline Round 1: Median 2.0 (0-9); n = 9 Round 2: Median 2.0 (0-7); n = 11 | -If indicated for neuropathic pain -Less than amitriptyline |
Mianserin Round 1: Median 5.0 (0-9); n = 7 Round 2: Median 0.0 (0-7); n = 11 | -Little used in practice compared with other drugs and little evidence available -No point really - it is pharmacologically similar to mirtazapine, which doesn't hit the white cells |